Hypothermic oxygenated machine perfusion reduces early allograft injury and improves post-transplant outcomes in extended criteria donation liver transplantation from donation after brain death

• Verfasst von: Czigány, Zoltán [VerfasserIn]
• Verfasst von: Pratschke, Johann [VerfasserIn]
• Verfasst von: Froněk, Jiří [VerfasserIn]
• Verfasst von: Guba, Markus [VerfasserIn]
• Verfasst von: Schöning, Wenzel [VerfasserIn]
• Verfasst von: Raptis, Dimitri Aristotle [VerfasserIn]
• Verfasst von: Andrassy, Joachim [VerfasserIn]
• Verfasst von: Kramer, Matthijs [VerfasserIn]
• Verfasst von: Strnad, Pavel [VerfasserIn]
• Verfasst von: Tolba, Rene Hany [VerfasserIn]
• Verfasst von: Liu, Wenjia [VerfasserIn]
• Verfasst von: Keller, Theresa [VerfasserIn]
• Verfasst von: Miller, Hannah [VerfasserIn]
• Verfasst von: Pavicevic, Sandra [VerfasserIn]
• Verfasst von: Uluk, Deniz [VerfasserIn]
• Verfasst von: Kocik, Matej [VerfasserIn]
• Verfasst von: Lurje, Isabella [VerfasserIn]
• Verfasst von: Trautwein, Christian [VerfasserIn]
• Verfasst von: Mehrabi, Arianeb [VerfasserIn]
• Verfasst von: Popescu, Irinel [VerfasserIn]
• Verfasst von: Vondran, Florian Wolfgang Rudolf [VerfasserIn]
• Verfasst von: Ju, Cynthia [VerfasserIn]
• Verfasst von: Tacke, Frank [VerfasserIn]
• Verfasst von: Neumann, Ulf Peter [VerfasserIn]
• Verfasst von: Lurje, Georg [VerfasserIn]
• Titel: Hypothermic oxygenated machine perfusion reduces early allograft injury and improves post-transplant outcomes in extended criteria donation liver transplantation from donation after brain death
• Titelzusatz: results from a multicenter randomized controlled trial (HOPE ECD-DBD)
• Verf.angabe: Zoltan Czigany, MD, PhD, Johann Pratschke, MD, Jiří Froněk, MD, Markus Guba, MD, Wenzel Schöning, MD, Dimitri Aristotle Raptis, MD, MSc, PhD, Joachim Andrassy, MD, Matthijs Kramer, MD, PhD, Pavel Strnad, MD, Rene Hany Tolba, MD, PhD, Wenjia Liu, MD, Theresa Keller, PhD, Hannah Miller, MD, Sandra Pavicevic, MD, Deniz Uluk, MD, Matej Kocik, MD, Isabella Lurje, MD, Christian Trautwein, MD, Arianeb Mehrabi, MD, Irinel Popescu, MD, Florian Wolfgang Rudolf Vondran, MD, Cynthia Ju, PhD, Frank Tacke, MD, PhD, Ulf Peter Neumann, MD, and Georg Lurje, MD
• E-Jahr: 2021
• Jahr: November 2021
• Umfang: 8 S.
• Fussnoten: Gesehen am 27.09.2022
• Titel Quelle: Enthalten in: Annals of surgery
• Ort Quelle: [Erscheinungsort nicht ermittelbar] : Lippincott Williams & Wilkins, 1885
• Jahr Quelle: 2021
• Band/Heft Quelle: 274(2021), 5 vom: Nov., Seite 705-712
• ISSN Quelle: 1528-1140
• DOI: doi:10.1097/SLA.0000000000005110
• Datenträger: Online-Ressource
• Sprache: eng
• K10plus-PPN: 1817581007

Abstract

Objective: - The aim of this study was to evaluate peak serum alanine aminotransferase (ALT) and postoperative clinical outcomes after hypothermic oxygenated machine perfusion (HOPE) versus static cold storage (SCS) in extended criteria donation (ECD) liver transplantation (LT) from donation after brain death (DBD). - Background: - HOPE might improve outcomes in LT, particularly in high-risk settings such as ECD organs after DBD, but this hypothesis has not yet been tested in a randomized controlled clinical trial (RCT). - Methods: - Between September 2017 and September 2020, 46 patients undergoing ECD-DBD LT from four centers were randomly assigned to HOPE (n = 23) or SCS (n = 23). Peak-ALT levels within 7 days following LT constituted the primary endpoint. Secondary endpoints included incidence of postoperative complications [Clavien-Dindo classification (CD), Comprehensive Complication Index (CCI)], length of intensive care- (ICU) and hospital-stay, and incidence of early allograft dysfunction (EAD). - Results: - Demographics were equally distributed between both groups [donor age: 72 (IQR: 59-78) years, recipient age: 62 (IQR: 55-65) years, labMELD: 15 (IQR: 9-25), 38 male and 8 female recipients]. HOPE resulted in a 47% decrease in serum peak ALT [418 (IQR: 221-828) vs 796 (IQR: 477-1195) IU/L, P = 0.030], a significant reduction in 90-day complications [44% vs 74% CD grade ≥3, P = 0.036; 32 (IQR: 12-56) vs 52 (IQR: 35-98) CCI, P = 0.021], and shorter ICU- and hospital-stays [5 (IQR: 4-8) vs 8 (IQR: 5-18) days, P = 0.045; 20 (IQR: 16-27) vs 36 (IQR: 23-62) days, P = 0.002] compared to SCS. A trend toward reduced EAD was observed for HOPE (17% vs 35%; P = 0.314). - Conclusion: - This multicenter RCT demonstrates that HOPE, in comparison to SCS, significantly reduces early allograft injury and improves post-transplant outcomes in ECD-DBD liver transplantation.